Browsing by Issue Date, starting with "2003"
Now showing 1 - 6 of 6
Results Per Page
Sort Options
- Carcinoma de células renais cístico: a revisão a propósito de um casoPublication . Cabral-Ribeiro, J; Sousa, L; Pardal, F; Ribeiro dos Santos, A
- Metastização cutânea em doente com neoplasia síncrona da próstata e da mamaPublication . Cabral-Ribeiro, J; Pereira, T; Sousa, L; Silva, A; Ribeiro dos Santos, A
- Polipose linfomatosa múltiplaPublication . Cabral-Ribeiro, J; Toscano, A; Antunes, C; Manso, F; Capelo, C
- Carcinoma do rim. Experiência do serviço de urologia do Hospital de São Marcos (1997-2002)Publication . Cabral-Ribeiro, J; Sousa, L; Carvalho, AP; Mendes, V; Silva, C; Garcia, P; Ribeiro dos Santos, A
- A whole genome screen for association with multiple sclerosis in Portuguese patientsPublication . Santos, M; Pinto-Basto, J; Rio, ME; Sá, MJ; Valença, A; Sá, A; Dinis, J; Figueiredo, J; Bigotte de Almeida, L; Coelho, I; Sawcer, S; Setakis, E; Compston, A; Sequeiros, J; Maciel, PMultiple sclerosis (MS) is common in Europe affecting up to 1:500 people. In an effort to identify genes influencing susceptibility to the disease, we have performed a population-based whole genome screen for association. In this study, 6000 microsatellite markers were typed in separately pooled DNA samples from MS patients (n=188) and matched controls (n=188). Interpretable data was obtained from 4661 of these markers. Refining analysis of the most promising markers identified 10 showing potential evidence for association.
- Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal studyPublication . Lafeuillade, A; Clumeck, N; Mallolas, J; Jaeger, H; Livrozet, JM; Ferreira, MS; Jonhson, S; Cheret, A; Antoun, Z; European Trizal team.PURPOSE: To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir (zidovudine, lamivudine, abacavir) after 48 weeks. METHOD: Patients treated with HAART >6 months with plasma HIV-1 RNA viral load (VL) <400 copies/mL and <50 copies/mL at screening were randomly assigned to continue HAART (103 patients) or to receive Trizivir (106 patients). Clinical LD was evaluated using a standardized patient questionnaire only at baseline, weeks 4 and 8, and then every 8 weeks until Week 48. Laboratory evaluation was performed every 4 weeks. RESULTS: The proportion of patients exhibiting >or=1 LD symptom at baseline was 40% in the Trizivir arm and 50% in HAART arm (difference not significant). After 48 weeks, the prevalence was 28% and 42% respectively (p =.03), and the median number of LD symptoms per patient was 2 in the Trizivir arm and 4 in the continued HAART arm (p =.016). Median decreases in cholesterol levels over the 48-week study period were greater in the Trizivir arm than in the continued HAART arm (-0.80 vs. -0.44 mmol/L; p lt.001). Median triglyceride levels decreased in the Trizivir arm but increased in the continued HAART arm (-0.17 and +0.01 mmol/L; p =.006). Suppression of VL was maintained in most patients with no differences between the two arms. CONCLUSION: A switch from "standard" HAART to Trizivir was associated with an improvement in clinical LD and blood lipid abnormalities after 48 weeks.